Overview
Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.
Indication
Used in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying.
Associated Conditions
- Cough
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Genus Lifesciences Inc. | 64950-342 | ORAL | 1.5 mg in 5 mL | 12/3/2021 | |
| Akorn | 50383-043 | ORAL | 1.5 mg in 5 mL | 3/11/2022 | |
| Actavis Pharma, Inc. | 0472-1030 | ORAL | 1.5 mg in 5 mL | 9/30/2022 | |
| Physicians Total Care, Inc. | 54868-5168 | ORAL | 1.5 mg in 5 mL | 12/15/2011 | |
| Genus Lifesciences Inc. | 64950-205 | ORAL | 1.5 mg in 1 1 | 12/3/2021 | |
| KVK-Tech, Inc. | 10702-150 | ORAL | 1.5 mg in 5 mL | 12/19/2018 | |
| Pharmaceutical Associates, Inc. | 0121-4811 | ORAL | 1.5 mg in 5 mL | 12/9/2021 | |
| Lupin Pharmaceuticals,Inc. | 43386-118 | ORAL | 1.5 mg in 1 1 | 1/30/2024 | |
| Bio-Pharm, Inc. | 59741-262 | ORAL | 1.5 mg in 5 mL | 1/16/2019 | |
| ATLANTIC BIOLOGICALS CORP. | 17856-0455 | ORAL | 1.5 mg in 5 mL | 4/7/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| ACIDOBYL | desbergers ltée, division of technilab inc. | 00086681 | Tablet - Oral | 0.5 MG | 12/31/1951 |
| ACIDOBYL & CASCARA | desbergers ltée, division of technilab inc. | 00086762 | Tablet - Oral | 0.5 MG | 12/31/1951 |
| DEBILINE H | lab nadeau ltée, division of technilab inc. | 00145653 | Tablet - Oral | 2.5 MG | 12/31/1951 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.